Search

The adoptive cell therapy afamitresgene autoleucel (afami-cel) demonstrated a favorable response and duration of response in select patients with metastatic synovial sarcoma, according to results from an international phase 2 clinical trial published recently in The Lancet. 

… Thursday, March 28, 2024 UPDATE August 2, 2024: The U.S. Food and Drug Administration (FDA) has  granted accelerated approval  for the immunotherapy afamitresgene autoleucel for the treatment of adults with  synovial sarcoma . The adoptive cell therapy afamitresgene autoleucel (afami-cel) demonstrated

Learn what detection of the polio virus in New York State means for you.

… Monday, September 12, 2022 Polio has been in the news after the poliovirus was detected in wastewater samples of several New York counties — including New York City — and a person was identified as having the disease by New York health officials in July. On September 9, Gov. Kathy Hochul declared a state

A new study from Memorial Sloan Kettering Cancer Center has found that high-dose radiation therapy administered alongside systemic therapy in patients with metastatic non-small cell lung cancer can help extend progression free survival.

… Sunday, October 24, 2021 A new study from Memorial Sloan Kettering Cancer Center found that high-dose radiation therapy administered alongside systemic therapy in patients with metastatic non-small cell lung cancer can help extend progression free survival. This is the first and largest randomized clinical

Epcoritamab plus R2 resulted in substantial increases in the objective response rate and progression-free survival compared to R2 alone, the co-primary endpoints of the trial. The triplet combination also outperformed the standard-of-care on the secondary endpoints of complete response rate and duration of response. Lorenzo Falchi, MD, presented the latest results for the study at the American Society of Hematology's 67th Annual Meeting and Exposition in Florida.

… Sunday, December 7, 2025 On November 18, 2025, the U.S. Food and Drug Administration (FDA) approved the triplet epcoritamab plus lenalidomide and rituximab (R 2 ) for patients with relapsed or refractory follicular lymphoma, based on groundbreaking results from the phase 3 EPCORE FL-1 Trial ( NCT05409066

Learn about a possible new treatment approach for soft tissue sarcomas.

… Monday, February 5, 2024 Epithelioid sarcoma , a rare aggressive cancer that usually strikes young adults, and rhabdoid tumors , which affect children, have long been difficult to treat. But the outlook for people with these subtypes of soft tissue sarcoma brightened in 2020 when the Food and Drug Administration

The FDA has granted accelerated approval to zenocutuzumab for treating patients with advanced pancreatic cancer or non-small cell lung cancer with an alteration called an NRG1 gene fusion, based on a phase 2 clinical trial led by an MSK investigator.

… Thursday, February 6, 2025 Zenocutuzumab (Bizengri ® ) is effective at treating many patients with advanced  pancreatic cancer or  non-small cell lung cancer (NSCLC)  that has an alteration called an  NRG1  gene fusion and whose disease progressed after other treatments, according to a study published

La FDA ha otorgado la aprobación acelerada a zenocutuzumab para el tratamiento de pacientes con cáncer de páncreas avanzado o cáncer pulmonar de células no pequeñas (CPCNP) con una alteración denominada fusión del gen NRG1, con base en un ensayo clínico de fase 2, liderado por una investigadora de MSK.

… Thursday, February 6, 2025 Zenocutuzumab (Bizengri ® ) es eficaz para tratar a muchos pacientes con  cáncer de páncreas avanzado o  cáncer pulmonar de células no pequeñas (CPCNP)  que presentan una alteración llamada fusión del gen  NRG1  y cuya enfermedad progresó después de otros tratamientos, según

The Society of Memorial Sloan Kettering Cancer Center (MSK) has announced that Richard J. O’Reilly, MD, has been named the inaugural recipient of The Society of Memorial Sloan Kettering Prize. This new award recognizes an individual who has made outstanding contributions to the field of pediatric oncology.

… Monday, May 2, 2016 The Society of Memorial Sloan Kettering Cancer Center (MSK) has announced that Richard J. O’Reilly, MD, has been named the inaugural recipient of The Society of Memorial Sloan Kettering Prize. This new award recognizes an individual who has made outstanding contributions to the field

When Jacqueline was in pain caused by bone metastases from lung cancer, she got help at a specialized MSK clinic. "It's unbelievable the difference it made," she says.

… Thursday, October 3, 2024 For Jacqueline Hickey, the pain was so severe at times that it interfered with her daily life. “It just hurt so bad, especially lying down at night. I got so sleep deprived,” she recalls. “During the day, it was hard to even lift a laundry basket or walk for exercise.” She has

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Thursday, December 7, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Lisa DeAngelis Named to amNY Metro and PoliticsNY’s Power Players in Healthcare List Lisa DeAngelis Named to amNY Metro and PoliticsNY’s Power Players in Healthcare List Lisa